EGFR and non-small cell lung carcinoma: Several studies reported that the efficacies for patients with EGFR-mutant NSCLC with brain, bone, or liver metastases were limited, and both progression-free survival (PFS) and overall survival (OS) of these patients were remarkably shorter than those of patients without these metastatic sites [12, 13].